Article
Analysis shows a maintained blood pressure lowering effect with fewer added medications following treatment with the Paradise Ultrasound Renal Denervation system Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced positive results from a combined analysis of six-month…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.…
Read More
Excerpt from the Press Release: MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced it has initiated MONARCH, a Phase…
Read More
– Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 – – Statistically significant and clinically meaningful reductions in all major symptom domains and secondary endpoints at week 4 with 50 mg of…
Read More
SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per year Only treatment approved for use beyond 12 months for GA, a chronic disease and leading cause of vision loss Excerpt from the Press Release: WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today…
Read More
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers Excerpt from the Press Release: NEWTOWN, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients…
Read More
FX-909 is a first-in-class small molecule inhibitor of the PPARG transcription factor for the potential treatment of advanced urothelial carcinoma Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 19, 2023 /PRNewswire/ — Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, today announced that the…
Read More
Excerpt from the Press Release: NNYVALE, Calif., Oct. 20, 2023 /PRNewswire/ — Riboscience, LLC, today announced the first presentation of data from the ongoing Phase 1 clinical trial of the ENPP1 inhibitor RBS2418 that will be delivered by Dr. Thomas U. Marron, MD, PhD, from Mount Sinai, New York at the European Society for Medical…
Read More
RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) – – RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – – RaniPill® HC shortlisted as a finalist by Fierce Life Sciences Innovation Awards – Excerpt from the Press Release: SAN JOSE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE)…
Read More
Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months Excerpt from the Press Release: MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company…
Read More